Closed · RFA-CA-23-043 · CFDA 93.393;93.394;93.395;93.396;93.399 · Discretionary
Single Source: AIDS and Cancer Specimen Resource (ACSR; UM1 Clinical Trials Not Allowed)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- January 9, 2024
- Close date
- -
- Expected awards
The verdict
Single Source: AIDS and Cancer Specimen Resource (ACSR; UM1 Clinical Trials Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 93.393;93.394;93.395;93.396;93.399
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Single Source: AIDS and Cancer Specimen Resource (ACSR; UM1 Clinical Trials Not Allowed) - is cataloged under number RFA-CA-23-043 and tied to CFDA assistance listing 93.393;93.394;93.395;93.396;93.399, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on November 2, 2023. The funding category is Discretionary, delivered as a cooperative agreement.
Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on January 9, 2024. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
January 9, 2024
Posted
November 2, 2023
Instrument
Cooperative Agreement
Description
Through this non-competitive single source cooperative agreement Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits an application from (-----institute name-----) with the intent of funding a single award to continue to support the AIDS and Cancer Specimen Resource (ACSR). This is a reissue of RFA-CA-18-012. The ACSRs mission is to address the specimen needs of clinician and basic researchers in HIV and HIV-associated malignancy research. The ACSR is an international repository with specimens that reflect different eras of the epidemic (notably pre-cART and post-cART), different regions of the world, and people of diverse genetic backgrounds with different environmental exposures. Specimens have been obtained from people with HIV (PWH), people at risk for acquiring HIV, and HIV-uninfected controls. Specimens have been obtained from participants in clinical trials, observational cohort studies, or other research studies conducted by HIV investigators and consortium. The ACSR uses informed approaches to prospectively curate specimens in the USA, sub-Saharan Africa and Latin America that will be most valuable for the research community. Specimens and associated data are made available to the research community-at-large at NO COST. A second key role of the ACSR, is to serve as the AMC Biorepository for the AIDS Malignancy Consortium (AMC). The AMC is an NCI funded, multicenter clinical trials cooperative group that performs clinical trials research in the treatment and prevention of HIV-associated malignancies. The ACSR is currently providing support for domestic (two), sub-Saharan African, and Latin American biorepositories for the AMC.
Eligibility
Grants.gov lists this opportunity under eligibility category code 23. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH Grants Information grantsinfo@nih.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |